H-Index
79
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
16%
Acceptance
Rate
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo

Medical Science Monitor Basic Research
AmJCaseRep

Annals
ISI-Home

eISSN: 1643-3750

Get your full text copy in PDF

Successful treatment of immune thrombocytopenic purpura (ITP) with the thrombopoietin-mimetic Romiplostim

John Meletis, Aikaterini Katsandris, Sophia D. Raptis, Marina Mantzourani

Med Sci Monit 2010; 16(8): CS100-102

ID: 881091


Background:    Romiplostim is a second-generation thrombopoietic receptor agonist that exerts its therapeutic effect by stimulating megakaryopoiesis.
    Case Report:    We report a patient with immune thrombocytopenic purpura refractory to other therapies including splenectomy, which was successfully managed with romiplostim. More specifically, the patient’s platelet count showed a 3-fold increase within 7 days following the first dose of romiplostim (from 33×109/l to 96×109/l).
    Conclusions:    Romiplostin is a new trombopoietin peptide mimetic drug, which seems to be very effective for the management of refractory chronic ITP in adults.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree